[go: up one dir, main page]

WO2009017719A3 - Modulators of ccr9 receptor and methods of use thereof - Google Patents

Modulators of ccr9 receptor and methods of use thereof Download PDF

Info

Publication number
WO2009017719A3
WO2009017719A3 PCT/US2008/009142 US2008009142W WO2009017719A3 WO 2009017719 A3 WO2009017719 A3 WO 2009017719A3 US 2008009142 W US2008009142 W US 2008009142W WO 2009017719 A3 WO2009017719 A3 WO 2009017719A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulators
ccr9 receptor
compounds
ccr9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/009142
Other languages
French (fr)
Other versions
WO2009017719A8 (en
WO2009017719A2 (en
Inventor
Eric C Anderson
Ronald J Biediger
Jie Chen
Brian Dupre
Pedro Lory
Robert V Market
Keith A Monk
Michael M Savage
Reginald Tennyson
Brandon M Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Priority to MX2010001187A priority Critical patent/MX2010001187A/en
Priority to AU2008282903A priority patent/AU2008282903B2/en
Priority to CA2692013A priority patent/CA2692013C/en
Priority to EP08794832A priority patent/EP2220065A2/en
Publication of WO2009017719A2 publication Critical patent/WO2009017719A2/en
Publication of WO2009017719A3 publication Critical patent/WO2009017719A3/en
Anticipated expiration legal-status Critical
Publication of WO2009017719A8 publication Critical patent/WO2009017719A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.
PCT/US2008/009142 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof Ceased WO2009017719A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2010001187A MX2010001187A (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof.
AU2008282903A AU2008282903B2 (en) 2007-07-30 2008-07-28 Modulators of CCR9 receptor and methods of use thereof
CA2692013A CA2692013C (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof
EP08794832A EP2220065A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96264007P 2007-07-30 2007-07-30
US60/962,640 2007-07-30

Publications (3)

Publication Number Publication Date
WO2009017719A2 WO2009017719A2 (en) 2009-02-05
WO2009017719A3 true WO2009017719A3 (en) 2009-04-23
WO2009017719A8 WO2009017719A8 (en) 2010-02-11

Family

ID=40305125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009142 Ceased WO2009017719A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof

Country Status (7)

Country Link
EP (1) EP2220065A2 (en)
KR (1) KR20100033418A (en)
AU (1) AU2008282903B2 (en)
CA (1) CA2692013C (en)
MX (1) MX2010001187A (en)
SG (1) SG183667A1 (en)
WO (1) WO2009017719A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020460B1 (en) 2009-01-12 2014-11-28 Пфайзер Лимитед Sulfonamide derivatives
EP2560636A4 (en) * 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL COMPOUNDS
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012051318A1 (en) * 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
CN118201912A (en) * 2021-10-28 2024-06-14 四国化成工业株式会社 Thiophene compound, synthesis method thereof and composition containing the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001002687A (en) * 1999-06-18 2001-01-09 Otsuka Pharmaceut Factory Inc Phosphonic acid diester derivatives
US20040180892A1 (en) * 2003-02-20 2004-09-16 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001002687A (en) * 1999-06-18 2001-01-09 Otsuka Pharmaceut Factory Inc Phosphonic acid diester derivatives
US20040180892A1 (en) * 2003-02-20 2004-09-16 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 9 January 2001 (2001-01-09), XP002515849, retrieved from STN Database accession no. 2001:18962 *

Also Published As

Publication number Publication date
AU2008282903A1 (en) 2009-02-05
CA2692013C (en) 2012-08-28
WO2009017719A8 (en) 2010-02-11
EP2220065A2 (en) 2010-08-25
WO2009017719A2 (en) 2009-02-05
MX2010001187A (en) 2010-03-04
AU2008282903B2 (en) 2011-06-30
SG183667A1 (en) 2012-09-27
KR20100033418A (en) 2010-03-29
CA2692013A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
IL192868A0 (en) 1,4-di substituted 3-cyano- pyridone perivatives and their use as positive mglur2-receptor modulators
TW200716624A (en) Compounds for modulating TRPV3 function
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
IL232313A0 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2010002028A (en) Methods and compositions for modulating t cells.
PT1858877E (en) 1,3 substituted diaryl ureas as modulators of kinase activity
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof
WO2006050333A3 (en) Methods and compositions for modulating apoptosis
WO2007002131A3 (en) Galk1s as modifiers of the pten/akt pathway and methods of use
WO2007041397A3 (en) Targeted pharmaceuticals and ligands
WO2008036422A3 (en) Vipr1s as modifiers of the e2f/rb pathway and methods of use
WO2008016996A3 (en) Methods of modulating metabolic memory
WO2009053895A3 (en) Quinoline urotensin-ii receptor antagonists
UY29756A1 (en) DERIVATIVES OF 5-PIRIDAZINIL-1-AZABICICLO (3.2.1) OCTANO, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
WO2006099183A3 (en) Nek8s as modifiers of the pten/akt pathway and methods of use
WO2007058860A3 (en) Mrhos as modifiers of the rho pathway and methods of use
WO2007002081A3 (en) Gfats as modifiers of the axin pathway and methods of use
UA97289C2 (en) Compounds and compositions thereof as grp119 activity modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2692013

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008282903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008794832

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107001995

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010519223

Country of ref document: JP

Ref document number: MX/A/2010/001187

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008282903

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1285/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: JP